Skip to main content
. 2014 Jul 27;35(10):1187–1194. doi: 10.1002/humu.22626

Table 1.

Pathogenic ABCA4 Variants in Patients of African American Descent

Patient Clinical Assessment
BCVA
CNV
ID Diagnosis Stage Onset decade OD OS analysis ABCA4 mutations
1 STGD1 2 8th 20/25 20/25 p.[(P1380L)];[?]
2 STGD1 2 5th 10/100 10/160 X p.[(R220C(;)R2107H)]
3 STGD1 1 4th 20/30 20/200 p.[(G1961E(;)D403V)]
4 STGD1 2–3 3rd 20/400 20/100 X p.[(W1408L(;)R2107H)]
5 STGD1 0 5th 20/200 20/50 X p.[(P62S)];[?]
6 STGD1 1 7th 20/25-2 20/25-3 X p.[(R2107H)];[?]
7 STGD1 N/A 4th 20/70+2 20/25-2 X p.[(P309R(;)R681*)]
8 STGD1 1 4th 20/15-3 20/20+1 X p.[(G991R(;)L1126P)]
9 STGD1 N/A 2nd 20/400 20/400 X c.5289del(;)p.(V989A)
10 STGD1 N/A N/A N/A N/A p.[(R2077G(;)R2107H)]
11 STGD1 2 3rd 20/200 20/200 X c.3523-1G>A(;)p.(R2107H)
12 STGD1 2 4th 20/20 20/20 X p.[(G991R)];[?]
13 STGD1 1 4th 20/70+2 20/25-2 no mutations found
14 STGD1 3 1st 20/400 20/400 X c.768G>T(;)p.(R2107H)
15 STGD1 1 5th 20/50-2 20/40 X p.[(V989A(;)R2107H(;)P870S)]
16 STGD1 2–3 1st 20/400 20/300 X p.[(G607R(;)R2040Q)]
17a STGD1 1 2nd 10/100-1 10/60-1 X p.[(P309R(;)R537C(;)R2107H)]
18 STGD1 2 1st 20/400 20/400 X c.5461-10T>C(;)p.(R2040Q)
19 STGD1 2 2nd 10/120+1 10/100-1 c.5461-10T>C(;)p.(E531G)
20 STGD1 1 3rd 20/80-2 20/125+1 No mutations found
21a STGD1 (BEM) 1 2nd 20/100 20/150 X p.[(G991R)];[(L1138P)]
22a STGD1 2 3rd 20/400 20/50-2 c.4537dup;p.(V1686M)
23 STGD1 2 2nd 20/125 20/125 p.[(R1640W)];[?]
24 CRD 3 1st CF CF p.[(T983A(;)L1729P)]
25 STGD1 1 4th 20/30+2 20/40-2 X p.[(V989A)];[(V989A)]
26 STGD1 3 2nd 20/150 20/25 p.[(N965S(;)R2040Q)]
27a CRD 3 1st CF CF X c.4540-2A>G;p.(R2107H)
28 STGD1 2 6th 20/30 20/40-1 X c.5461-10T>C;[?]
29 STGD1 1 6th 20/20 20/20 X p.[(F1015L)];[?]
30 STGD1 (BEM) 1 5th 20/50 20/30 No mutations found
31 STGD1 (BEM) 1 6th 20/20 20/20 p.[(R2107H)];[?]
32 STGD1 (BEM) 1 3rd 20/20 20/20 X p.[(R1300*(;)R2106C)]
33 STGD1 (BEM) 1 5th 20/100 20/125 p.[(R2107H)];[?]
34 STGD1 3 3rd LP LP p.[(R2107H)];[?]
35 STGD1 2 5th 20/40+1 20/40 X p.[(W339G(;)R2107H)]
36 STGD1 3 1st 20/30 20/40 No mutations found
37 STGD1 1 5th 20/25 20/25-1 p.[(I975M(;)K1978E)]
38 STGD1 2 2nd 20/200 20/200 p.[(V989A)];[?]
39 STGD1 1 3rd 20/100-1 20/200+1 c.302+1G>A(;)p.(R2107H)
40 STGD1 (BEM) 1 7th 20/20-3 20/20-3 p.[(R2107H)];[(R2107H)]
41 STGD1 1 3rd 30/30-2 20/100 No mutations found
42 STGD1 (BEM) 1 5th 20/40-2 20/50-2 No mutations found
43 CRD N/A 3rd 5/180+1 5/160+1 X p.[(V989A)];[?]
44a STGD1 2 N/A N/A N/A c.4253+4C>T(;)p.[(G1961E(;)R2107H)]

Nucleotide positions and protein translation correspond to CCDS747.1 and NP_000341.2, respectively. Nucleotide numbering uses the A of the ATG translation initiation start site as nucleotide 1.

BCVA: best corrected visual acuity; CNV: copy number variation; N/A: not available; CF: counting fingers; LP: light perception.

a

The variants are confirmed on different chromosomes.